| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.673 | 0.003 | 0.874 | GABA receptor agonist | 0.874 0.002 DBMET00299 0.598 0.003 DBMET00300 0.874 0.002 DBMET00135 | DBMET00135 | |
| 0.361 | 0.004 | 0.361 | GABA A receptor agonist | 0.118 0.025 DBMET00299 0.318 0.004 DBMET00300 0.118 0.025 DBMET00135 | ||
| 0.3 | 0.004 | 0.332 | GABA A receptor antagonist | 0.071 0.025 DBMET00299 0.332 0.004 DBMET00300 0.071 0.025 DBMET00135 | DBMET00300 | |
| 0.275 | 0.004 | 0.317 | GABA receptor antagonist | 0.062 0.031 DBMET00299 0.317 0.004 DBMET00300 0.062 0.031 DBMET00135 | DBMET00300 | |
| 0.215 | 0.004 | 0.215 | Benzodiazepine agonist | 0.11 0.02 DBMET00299 0.149 0.008 DBMET00300 0.11 0.02 DBMET00135 | ||
| 0.194 | 0.061 | 0.194 | Amyloid beta precursor protein antagonist | 0.145 0.107 DBMET00300 | ||
| 0.109 | 0.005 | 0.13 | GABA B receptor antagonist | 0.046 0.024 DBMET00299 0.13 0.004 DBMET00300 0.046 0.024 DBMET00135 0.042 0.032 DBMET00137 | DBMET00300 | |
| 0.152 | 0.048 | 0.158 | Aurora-C kinase inhibitor | 0.116 0.115 DBMET00299 0.158 0.042 DBMET00300 0.116 0.115 DBMET00135 | DBMET00300 | |
| 0.213 | 0.11 | 0.213 | Spasmolytic | 0.197 0.122 DBMET00299 0.197 0.122 DBMET00135 | ||
| 0.107 | 0.012 | 0.107 | 5 Hydroxytryptamine 3 agonist | 0.098 0.016 DBMET00300 0.079 0.028 DBMET00137 | ||
| 0.074 | 0.011 | 0.074 | Bromodomain-containing protein 3 inhibitor | 0.051 0.032 DBMET00299 0.064 0.017 DBMET00300 0.051 0.032 DBMET00135 | ||
| 0.049 | 0.011 | 0.049 | Calcitonin gene-related peptide antagonist | 0.045 0.012 DBMET00300 | ||
| 0.082 | 0.059 | 0.085 | Transforming growth factor beta 3 antagonist | 0.085 0.05 DBMET00299 0.082 0.059 DBMET00300 0.085 0.05 DBMET00135 | DBMET00135 | |
| 0.065 | 0.048 | 0.065 | 5 Hydroxytryptamine 3A antagonist | 0.06 0.056 DBMET00300 | ||
| 0.033 | 0.025 | 0.033 | ADAM10 endopeptidase inhibitor | 0.032 0.026 DBMET00300 | ||
| 0.032 | 0.028 | 0.032 | Benzodiazepine receptor peripheral-type antagonist | |||
| 0.043 | 0.044 | 0.045 | Benzodiazepine antagonist | 0.045 0.039 DBMET00137 | DBMET00137 | |
| 0.052 | 0.058 | 0.059 | Purinergic P2 antagonist | 0.059 0.049 DBMET00300 | DBMET00300 | |
| 0.071 | 0.082 | 0.101 | Acetylcholine agonist | 0.101 0.045 DBMET00299 0.101 0.045 DBMET00135 | DBMET00135 | |
| 0.037 | 0.05 | 0.044 | Glutamate (mGluR5) agonist | 0.044 0.034 DBMET00137 | DBMET00137 | |
| 0.189 | 0.222 | 0.614 | GABA C receptor rho-3 antagonist | 0.614 0.006 DBMET00137 | DBMET00137 | |
| 0.084 | 0.125 | 0.105 | Activin receptor-like kinase 4 inhibitor | 0.105 0.076 DBMET00300 | DBMET00300 | |
| 0.029 | 0.072 | 0.06 | Nerve growth factor antagonist | 0.06 0.01 DBMET00137 | DBMET00137 | |
| 0.026 | 0.071 | 0.04 | Neurokinin 1 antagonist | 0.04 0.029 DBMET00299 0.04 0.029 DBMET00135 | DBMET00135 | |
| 0.073 | 0.119 | 0.205 | 5 Hydroxytryptamine 3A agonist | 0.205 0.014 DBMET00137 | DBMET00137 | |
| 0.031 | 0.08 | 0.046 | Neurokinin antagonist | 0.046 0.04 DBMET00299 0.046 0.04 DBMET00135 | DBMET00135 | |
| 0.013 | 0.062 | 0.03 | Acetylcholine M4 receptor agonist | 0.03 0.022 DBMET00137 | DBMET00137 | |
| 0.015 | 0.067 | 0.041 | Potassium channel small-conductance Ca-activated activator | 0.041 0.015 DBMET00137 | DBMET00137 | |
| 0.008 | 0.065 | 0.016 | Nicotinic alpha4 receptor agonist | 0.016 0.011 DBMET00137 | DBMET00137 | |
| 0.022 | 0.088 | 0.042 | Glutamate (mGluR group I) agonist | 0.042 0.04 DBMET00137 | DBMET00137 | |
| 0.018 | 0.087 | 0.037 | Vascular adhesion protein 1 inhibitor | 0.037 0.03 DBMET00137 | DBMET00137 | |
| 0.01 | 0.094 | 0.037 | Nicotinic alpha4beta2 receptor agonist | 0.037 0.01 DBMET00137 | DBMET00137 | |
| 0.053 | 0.149 | 0.085 | Protein kinase C mu inhibitor | 0.085 0.074 DBMET00300 | DBMET00300 | |
| 0.011 | 0.11 | 0.023 | Factor XIII inhibitor | 0.023 0.01 DBMET00137 | DBMET00137 | |
| 0.058 | 0.16 | 0.102 | Bromodomain-containing protein 2 inhibitor | 0.102 0.038 DBMET00137 | DBMET00137 | |
| 0.038 | 0.14 | 0.076 | Corticotropin releasing factor 2 receptor antagonist | 0.076 0.021 DBMET00137 | DBMET00137 | |
| 0.17 | 0.278 | 0.302 | Analgesic | 0.302 0.14 DBMET00299 0.302 0.14 DBMET00135 | DBMET00135 | |
| 0.024 | 0.144 | 0.046 | Cholesterol esterase inhibitor | 0.046 0.036 DBMET00137 | DBMET00137 | |
| 0.031 | 0.154 | 0.071 | Protein kinase C beta inhibitor | 0.071 0.046 DBMET00137 | DBMET00137 | |
| 0.007 | 0.144 | 0.016 | CC chemokine 9 receptor antagonist | 0.016 0.015 DBMET00137 | DBMET00137 | |
| 0.033 | 0.183 | 0.059 | Phosphodiesterase 1A inhibitor | 0.059 0.044 DBMET00137 | DBMET00137 | |
| 0.051 | 0.21 | 0.108 | mTOR complex 2 inhibitor | 0.108 0.025 DBMET00137 | DBMET00137 | |
| 0.051 | 0.211 | 0.102 | Protein kinase C gamma inhibitor | 0.102 0.074 DBMET00137 | DBMET00137 | |
| 0.203 | 0.375 | 0.536 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.536 0.02 DBMET00137 | DBMET00137 | |
| 0.007 | 0.18 | 0.042 | Nicotinic alpha3beta4 receptor agonist | 0.042 0.009 DBMET00137 | DBMET00137 | |
| 0.039 | 0.213 | 0.089 | Protein kinase C delta inhibitor | 0.089 0.064 DBMET00299 0.089 0.064 DBMET00135 | DBMET00135 | |
| 0.018 | 0.208 | 0.05 | Thymidine kinase inhibitor | 0.05 0.019 DBMET00137 | DBMET00137 | |
| 0.017 | 0.213 | 0.061 | Cyclin-dependent kinase 6 inhibitor | 0.061 0.04 DBMET00137 | DBMET00137 | |
| 0.015 | 0.216 | 0.106 | Acetylcholine M5 receptor agonist | 0.106 0.017 DBMET00137 | DBMET00137 | |
| 0.068 | 0.27 | 0.125 | Cyclin-dependent kinase 8 inhibitor | 0.125 0.11 DBMET00137 | DBMET00137 | |
| 0.036 | 0.245 | 0.162 | Bronchodilator | 0.162 0.028 DBMET00299 0.162 0.028 DBMET00135 | DBMET00135 | |
| 0.003 | 0.215 | 0.02 | Cyclin T1 inhibitor | 0.02 0.011 DBMET00137 | DBMET00137 | |
| 0.027 | 0.251 | 0.065 | Aryl hydrocarbon receptor antagonist | 0.065 0.044 DBMET00137 | DBMET00137 | |
| 0.07 | 0.295 | 0.273 | GABA C receptor rho-2 antagonist | 0.273 0.008 DBMET00137 | DBMET00137 | |
| 0.032 | 0.267 | 0.087 | Caspase 7 inhibitor | 0.087 0.047 DBMET00137 | DBMET00137 | |
| 0.008 | 0.247 | 0.031 | MAP3K8 inhibitor | 0.031 0.017 DBMET00137 | DBMET00137 | |
| 0.008 | 0.251 | 0.027 | 5 Hydroxytryptamine 6 agonist | 0.027 0.023 DBMET00137 | DBMET00137 | |
| 0.035 | 0.285 | 0.089 | Interleukin 1 beta converting enzyme inhibitor | 0.089 0.073 DBMET00137 | DBMET00137 | |
| 0.013 | 0.269 | 0.058 | Histamine H1 receptor agonist | 0.058 0.01 DBMET00137 | DBMET00137 | |
| 0.025 | 0.283 | 0.112 | Glutamate (mGluR7) antagonist | 0.112 0.006 DBMET00137 | DBMET00137 | |
| 0.014 | 0.272 | 0.037 | Protein kinase (CK2) beta inhibitor | 0.037 0.016 DBMET00137 | DBMET00137 | |
| 0.005 | 0.269 | 0.014 | Cyclin D2 inhibitor | 0.014 0.007 DBMET00137 | DBMET00137 | |
| 0.012 | 0.283 | 0.038 | Ceramide glucosyltransferase inhibitor | 0.038 0.021 DBMET00137 | DBMET00137 | |
| 0.012 | 0.294 | 0.041 | Glutamate (mGluR1a) antagonist | 0.041 0.028 DBMET00137 | DBMET00137 | |
| 0.015 | 0.302 | 0.049 | HCV NS3/NS4A protease inhibitor | 0.049 0.033 DBMET00137 | DBMET00137 | |
| 0.026 | 0.317 | 0.082 | Protein kinase C zeta inhibitor | 0.082 0.081 DBMET00137 | DBMET00137 | |
| 0.02 | 0.313 | 0.041 | CF transmembrane conductance regulator antagonist | 0.041 0.024 DBMET00137 | DBMET00137 | |
| 0.008 | 0.304 | 0.028 | Integrin alpha2beta1 antagonist | 0.028 0.015 DBMET00137 | DBMET00137 | |
| 0.014 | 0.312 | 0.089 | Nicotinic alpha4beta2 receptor antagonist | 0.089 0.041 DBMET00137 | DBMET00137 | |
| 0.009 | 0.316 | 0.031 | Thymidine phosphorylase inhibitor | 0.031 0.011 DBMET00137 | DBMET00137 | |
| 0.012 | 0.32 | 0.212 | Carbamoyl phosphate synthetase inhibitor | 0.212 0.007 DBMET00137 | DBMET00137 | |
| 0.067 | 0.378 | 0.202 | Cyclic AMP phosphodiesterase inhibitor | 0.202 0.092 DBMET00137 | DBMET00137 | |
| 0.011 | 0.325 | 0.032 | Glutamate (mGluR4) agonist | 0.032 0.029 DBMET00137 | DBMET00137 | |
| 0.016 | 0.331 | 0.064 | Cyclin D1 inhibitor | 0.064 0.036 DBMET00137 | DBMET00137 | |
| 0.094 | 0.413 | 0.192 | Ca2+-transporting ATPase inhibitor | 0.192 0.004 DBMET00137 | DBMET00137 | |
| 0.019 | 0.342 | 0.04 | Alpha 1L adrenoreceptor agonist | 0.04 0.037 DBMET00300 | DBMET00300 | |
| 0.072 | 0.399 | 0.287 | DNA synthesis inhibitor | 0.287 0.048 DBMET00137 | DBMET00137 | |
| 0.016 | 0.347 | 0.048 | CC chemokine 4 receptor antagonist | 0.048 0.031 DBMET00137 | DBMET00137 | |
| 0.013 | 0.345 | 0.156 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.156 0.008 DBMET00137 | DBMET00137 | |
| 0.05 | 0.387 | 0.124 | Transcription factor STAT6 inhibitor | 0.124 0.054 DBMET00137 | DBMET00137 | |
| 0.024 | 0.368 | 0.088 | Ephrin antagonist | 0.088 0.075 DBMET00299 0.088 0.075 DBMET00135 | DBMET00135 | |
| 0.006 | 0.351 | 0.031 | Acid ceramidase inhibitor | 0.031 0.008 DBMET00137 | DBMET00137 | |
| 0.011 | 0.362 | 0.037 | MAP3K5 inhibitor | 0.037 0.03 DBMET00137 | DBMET00137 | |
| 0.057 | 0.409 | 0.136 | MAP kinase 3 inhibitor | 0.136 0.092 DBMET00137 | DBMET00137 | |
| 0.005 | 0.361 | 0.068 | Guanylate cyclase inhibitor | 0.068 0.005 DBMET00137 | DBMET00137 | |
| 0.038 | 0.395 | 0.099 | Phosphodiesterase 6D inhibitor | 0.099 0.055 DBMET00137 | DBMET00137 | |
| 0.015 | 0.372 | 0.046 | Vanilloid 3 antagonist | 0.046 0.012 DBMET00137 | DBMET00137 | |
| 0.006 | 0.365 | 0.047 | Purinergic P2Y15 antagonist | 0.047 0.004 DBMET00137 | DBMET00137 | |
| 0.046 | 0.407 | 0.137 | Glutamate release inhibitor | 0.137 0.014 DBMET00137 | DBMET00137 | |
| 0.004 | 0.369 | 0.042 | Phosphoglycerate kinase inhibitor | 0.042 0.018 DBMET00137 | DBMET00137 | |
| 0.022 | 0.398 | 0.226 | Cystathionine beta-synthase inhibitor | 0.226 0.019 DBMET00137 | DBMET00137 | |
| 0.019 | 0.396 | 0.148 | Falcipain 3 inhibitor | 0.148 0.038 DBMET00137 | DBMET00137 | |
| 0.031 | 0.411 | 0.251 | NADH dehydrogenase inhibitor | 0.251 0.008 DBMET00137 | DBMET00137 | |
| 0.009 | 0.391 | 0.038 | Integrin alpha2 antagonist | 0.038 0.023 DBMET00137 | DBMET00137 | |
| 0.01 | 0.394 | 0.031 | Glucosylceramidase stimulant | 0.031 0.011 DBMET00137 | DBMET00137 | |
| 0.029 | 0.414 | 0.174 | Electrolyte absorption antagonist | 0.174 0.012 DBMET00137 | DBMET00137 | |
| 0.01 | 0.395 | 0.041 | Tryptophan 5 hydroxylase inhibitor | 0.041 0.013 DBMET00137 | DBMET00137 | |
| 0.051 | 0.438 | 0.126 | DNA repair enzyme inhibitor | 0.126 0.061 DBMET00137 | DBMET00137 | |
| 0.019 | 0.407 | 0.067 | Orexin receptor 1 antagonist | 0.067 0.066 DBMET00137 | DBMET00137 | |
| 0.076 | 0.465 | 0.299 | RNA-directed DNA polymerase inhibitor | 0.299 0.032 DBMET00137 | DBMET00137 | |
| 0.114 | 0.505 | 0.468 | Caspase 9 stimulant | 0.468 0.074 DBMET00137 | DBMET00137 | |
| 0.002 | 0.394 | 0.01 | Purinergic P2Y2 agonist | 0.01 0.008 DBMET00137 | DBMET00137 | |
| 0.033 | 0.425 | 0.131 | Lanosterol 14 alpha demethylase inhibitor | 0.131 0.021 DBMET00137 | DBMET00137 | |
| 0.006 | 0.4 | 0.07 | Alpha 1d adrenoreceptor agonist | 0.07 0.007 DBMET00137 | DBMET00137 | |
| 0.034 | 0.428 | 0.107 | Interleukin 8 antagonist | 0.107 0.081 DBMET00137 | DBMET00137 | |
| 0.006 | 0.406 | 0.032 | Nicotinic acid receptor agonist | 0.032 0.031 DBMET00137 | DBMET00137 | |
| 0.004 | 0.406 | 0.018 | Alpha 2b adrenoreceptor agonist | 0.018 0.016 DBMET00137 | DBMET00137 | |
| 0.032 | 0.436 | 0.076 | MDM2 inhibitor | 0.076 0.026 DBMET00137 | DBMET00137 | |
| 0.004 | 0.411 | 0.033 | Kainate receptor 2 antagonist | 0.033 0.028 DBMET00137 | DBMET00137 | |
| 0.012 | 0.425 | 0.037 | Adenosine uptake inhibitor | 0.037 0.017 DBMET00137 | DBMET00137 | |
| 0.023 | 0.438 | 0.113 | Exportin-1 inhibitor | 0.113 0.005 DBMET00137 | DBMET00137 | |
| 0.031 | 0.448 | 0.139 | Acetylcholine release stimulant | 0.139 0.024 DBMET00137 | DBMET00137 | |
| 0.005 | 0.421 | 0.025 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.025 0.007 DBMET00137 | DBMET00137 | |
| 0.001 | 0.419 | 0.02 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.02 0.004 DBMET00137 | DBMET00137 | |
| 0.013 | 0.435 | 0.063 | Dopamine beta hydroxylase inhibitor | 0.063 0.012 DBMET00137 | DBMET00137 | |
| 0.024 | 0.446 | 0.223 | GABA C receptor rho-1 antagonist | 0.223 0.005 DBMET00137 | DBMET00137 | |
| 0.013 | 0.436 | 0.047 | Purinergic P2X4 antagonist | 0.047 0.03 DBMET00137 | DBMET00137 | |
| 0.013 | 0.436 | 0.106 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.106 0.01 DBMET00137 | DBMET00137 | |
| 0.019 | 0.449 | 0.214 | Creatine kinase inhibitor | 0.214 0.009 DBMET00137 | DBMET00137 | |
| 0.07 | 0.501 | 0.537 | 5 Hydroxytryptamine release stimulant | 0.537 0.022 DBMET00137 | DBMET00137 | |
| 0.102 | 0.534 | 0.274 | 5 Hydroxytryptamine 3E antagonist | 0.274 0.008 DBMET00137 | DBMET00137 | |
| 0.021 | 0.454 | 0.058 | Phosphodiesterase 1C inhibitor | 0.058 0.053 DBMET00137 | DBMET00137 | |
| 0.027 | 0.462 | 0.109 | Vanilloid 4 agonist | 0.109 0.011 DBMET00137 | DBMET00137 | |
| 0.003 | 0.441 | 0.033 | Methionyl aminopeptidase 1 inhibitor | 0.033 0.021 DBMET00137 | DBMET00137 | |
| 0.003 | 0.444 | 0.022 | Imidazoline I1 receptor antagonist | 0.022 0.013 DBMET00137 | DBMET00137 | |
| 0.017 | 0.459 | 0.123 | Histamine N-methyltransferase inhibitor | 0.123 0.028 DBMET00137 | DBMET00137 | |
| 0.019 | 0.461 | 0.398 | Ferrochelatase inhibitor | 0.398 0.004 DBMET00137 | DBMET00137 | |
| 0.001 | 0.444 | 0.009 | DNA topoisomerase III inhibitor | 0.009 0.004 DBMET00137 | DBMET00137 | |
| 0.039 | 0.485 | 0.152 | Pregnane X receptor agonist | 0.152 0.05 DBMET00137 | DBMET00137 | |
| 0.014 | 0.462 | 0.053 | Glutamate (mGluR4) antagonist | 0.053 0.018 DBMET00137 | DBMET00137 | |
| 0.002 | 0.453 | 0.052 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.052 0.008 DBMET00137 | DBMET00137 | |
| 0.013 | 0.469 | 0.108 | Alkylator | 0.108 0.08 DBMET00137 | DBMET00137 | |
| 0.009 | 0.465 | 0.06 | Adenosine deaminase inhibitor | 0.06 0.021 DBMET00137 | DBMET00137 | |
| 0.009 | 0.466 | 0.031 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.031 0.01 DBMET00137 | DBMET00137 | |
| 0.03 | 0.489 | 0.131 | TRPA1 agonist | 0.131 0.047 DBMET00137 | DBMET00137 | |
| 0.002 | 0.461 | 0.018 | Alpha 2a adrenoreceptor agonist | 0.018 0.011 DBMET00137 | DBMET00137 | |
| 0.008 | 0.476 | 0.033 | Complement factor 1s inhibitor | 0.033 0.005 DBMET00137 | DBMET00137 | |
| 0.084 | 0.553 | 0.157 | Heat shock protein 70 antagonist | 0.157 0.033 DBMET00137 | DBMET00137 | |
| 0.007 | 0.479 | 0.039 | AMPA 4 receptor antagonist | 0.039 0.028 DBMET00137 | DBMET00137 | |
| 0.005 | 0.481 | 0.048 | Glutamate (mGluR3) antagonist | 0.048 0.014 DBMET00137 | DBMET00137 | |
| 0.014 | 0.491 | 0.084 | Potassium channel (Tandem pore domain) blocker | 0.084 0.026 DBMET00137 | DBMET00137 | |
| 0.003 | 0.482 | 0.094 | Fumarate hydratase inhibitor | 0.094 0.006 DBMET00137 | DBMET00137 | |
| 0.008 | 0.488 | 0.083 | Alpha-mannosidase inhibitor | 0.083 0.01 DBMET00137 | DBMET00137 | |
| 0.006 | 0.486 | 0.192 | Acyl-CoA dehydrogenase inhibitor | 0.192 0.006 DBMET00137 | DBMET00137 | |
| 0.013 | 0.495 | 0.05 | Glutamate (mGluR group III) antagonist | 0.05 0.021 DBMET00137 | DBMET00137 | |
| 0.013 | 0.496 | 0.075 | Potassium channel intermediate-conductance Ca-activated blocker | 0.075 0.022 DBMET00137 | DBMET00137 | |
| 0.011 | 0.494 | 0.041 | Glutamate (mGluR group III) agonist | 0.041 0.033 DBMET00137 | DBMET00137 | |
| 0.015 | 0.506 | 0.101 | MAP kinase kinase 1 inhibitor | 0.101 0.055 DBMET00137 | DBMET00137 | |
| 0.006 | 0.501 | 0.023 | Methylmalonyl-CoA mutase inhibitor | 0.023 0.005 DBMET00137 | DBMET00137 | |
| 0.034 | 0.529 | 0.277 | Adenylate kinase inhibitor | 0.277 0.008 DBMET00137 | DBMET00137 | |
| 0.017 | 0.513 | 0.335 | UDP-glucose 4-epimerase inhibitor | 0.335 0.009 DBMET00137 | DBMET00137 | |
| 0.006 | 0.503 | 0.072 | Mannosidase inhibitor | 0.072 0.011 DBMET00137 | DBMET00137 | |
| 0.016 | 0.517 | 0.05 | Heme oxygenase inhibitor | 0.05 0.013 DBMET00137 | DBMET00137 | |
| 0.005 | 0.508 | 0.092 | NMDA receptor glycine site agonist | 0.092 0.021 DBMET00137 | DBMET00137 | |
| 0.007 | 0.512 | 0.034 | Estrogen-related receptor gamma antagonist | 0.034 0.009 DBMET00137 | DBMET00137 | |
| 0.032 | 0.537 | 0.23 | Polo-like kinase-3 inhibitor | 0.23 0.031 DBMET00299 0.23 0.031 DBMET00135 | DBMET00135 | |
| 0.015 | 0.526 | 0.063 | Nicotinic alpha3beta2 receptor antagonist | 0.063 0.023 DBMET00137 | DBMET00137 | |
| 0.003 | 0.516 | 0.061 | Geranyltranstransferase inhibitor | 0.061 0.013 DBMET00137 | DBMET00137 | |
| 0.006 | 0.52 | 0.208 | Biliverdin reductase inhibitor | 0.208 0.005 DBMET00137 | DBMET00137 | |
| 0.002 | 0.517 | 0.033 | Lysine carboxypeptidase inhibitor | 0.033 0.013 DBMET00137 | DBMET00137 | |
| 0.003 | 0.524 | 0.11 | Ornithine carbamoyltransferase inhibitor | 0.11 0.014 DBMET00137 | DBMET00137 | |
| 0.002 | 0.526 | 0.019 | Purinergic P2Y1 agonist | 0.019 0.007 DBMET00137 | DBMET00137 | |
| 0.017 | 0.545 | 0.142 | Nav1.6 sodium channel blocker | 0.142 0.063 DBMET00137 | DBMET00137 | |
| 0.014 | 0.543 | 0.161 | Aryl hydrocarbon receptor agonist | 0.161 0.127 DBMET00137 | DBMET00137 | |
| 0.087 | 0.616 | 0.427 | 5 Hydroxytryptamine uptake stimulant | 0.427 0.01 DBMET00137 | DBMET00137 | |
| 0.018 | 0.548 | 0.175 | I kappa B kinase epsilon inhibitor | 0.175 0.094 DBMET00137 | DBMET00137 | |
| 0.012 | 0.544 | 0.256 | Anesthetic general | 0.256 0.048 DBMET00137 | DBMET00137 | |
| 0.005 | 0.539 | 0.041 | Delayed rectifier potassium channel blocker | 0.041 0.019 DBMET00137 | DBMET00137 | |
| 0.013 | 0.547 | 0.132 | Cytidine deaminase inhibitor | 0.132 0.089 DBMET00137 | DBMET00137 | |
| 0.046 | 0.583 | 0.411 | Histamine release inhibitor | 0.411 0.07 DBMET00137 | DBMET00137 | |
| 0 | 0.539 | 0.006 | CC chemokine 6 receptor agonist | 0.006 0.004 DBMET00137 | DBMET00137 | |
| 0.015 | 0.56 | 0.103 | Caspase 3 inhibitor | 0.103 0.086 DBMET00137 | DBMET00137 | |
| 0.028 | 0.575 | 0.115 | D-Ala-D-Ala ligase inhibitor | 0.115 0.016 DBMET00137 | DBMET00137 | |
| 0.038 | 0.586 | 0.21 | Neuropeptide Y2 antagonist | 0.21 0.103 DBMET00137 | DBMET00137 | |
| 0.001 | 0.549 | 0.022 | Nicotinic acid receptor 1 antagonist | 0.022 0.007 DBMET00137 | DBMET00137 | |
| 0.013 | 0.568 | 0.144 | Microtubule formation inhibitor | 0.144 0.041 DBMET00137 | DBMET00137 | |
| 0.008 | 0.564 | 0.054 | 5 Hydroxytryptamine 7 agonist | 0.054 0.043 DBMET00137 | DBMET00137 | |
| 0.005 | 0.561 | 0.044 | Toll-Like receptor 2 agonist | 0.044 0.027 DBMET00137 | DBMET00137 | |
| 0.02 | 0.577 | 0.273 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.273 0.008 DBMET00137 | DBMET00137 | |
| 0.005 | 0.563 | 0.359 | Alcohol oxidase inhibitor | 0.359 0.004 DBMET00137 | DBMET00137 | |
| 0.01 | 0.57 | 0.046 | Potassium channel Kv1.1 blocker | 0.046 0.016 DBMET00137 | DBMET00137 | |
| 0.012 | 0.574 | 0.072 | Cathepsin G inhibitor | 0.072 0.051 DBMET00137 | DBMET00137 | |
| 0.008 | 0.574 | 0.065 | Secretase beta inhibitor | 0.065 0.058 DBMET00137 | DBMET00137 | |
| 0.022 | 0.589 | 0.165 | Cell wall synthesis inhibitor | 0.165 0.051 DBMET00137 | DBMET00137 | |
| 0.013 | 0.583 | 0.257 | GABA C receptor antagonist | 0.257 0.006 DBMET00137 | DBMET00137 | |
| 0.009 | 0.58 | 0.124 | CYP2A6 inhibitor | 0.124 0.025 DBMET00137 | DBMET00137 | |
| 0.013 | 0.585 | 0.526 | GABA C receptor agonist | 0.526 0.003 DBMET00137 | DBMET00137 | |
| 0.028 | 0.6 | 0.073 | Calcium channel P-type blocker | 0.073 0.022 DBMET00137 | DBMET00137 | |
| 0.01 | 0.586 | 0.072 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.072 0.004 DBMET00137 | DBMET00137 | |
| 0.005 | 0.581 | 0.031 | Carboxypeptidase B inhibitor | 0.031 0.027 DBMET00137 | DBMET00137 | |
| 0.056 | 0.64 | 0.38 | Calcium channel activator | 0.38 0.033 DBMET00137 | DBMET00137 | |
| 0.023 | 0.608 | 0.57 | Aldehyde oxidase inhibitor | 0.57 0.023 DBMET00137 | DBMET00137 | |
| 0.033 | 0.619 | 0.233 | Neurotrophic factor enhancer | 0.233 0.049 DBMET00137 | DBMET00137 | |
| 0.01 | 0.597 | 0.108 | Phospholipase D inhibitor | 0.108 0.011 DBMET00137 | DBMET00137 | |
| 0.005 | 0.592 | 0.053 | Prolyl endopeptidase inhibitor | 0.053 0.032 DBMET00137 | DBMET00137 | |
| 0.063 | 0.653 | 0.394 | Tyrosine 3 hydroxylase inhibitor | 0.394 0.009 DBMET00137 | DBMET00137 | |
| 0.007 | 0.597 | 0.063 | Epithelial sodium channel blocker | 0.063 0.025 DBMET00137 | DBMET00137 | |
| 0.013 | 0.604 | 0.123 | Purinergic P2X1 antagonist | 0.123 0.011 DBMET00137 | DBMET00137 | |
| 0.014 | 0.604 | 0.099 | Beta glucuronidase inhibitor | 0.099 0.071 DBMET00137 | DBMET00137 | |
| 0.004 | 0.595 | 0.218 | Phosphofructokinase-1 inhibitor | 0.218 0.009 DBMET00137 | DBMET00137 | |
| 0.005 | 0.597 | 0.058 | Oxytocin agonist | 0.058 0.019 DBMET00137 | DBMET00137 | |
| 0.001 | 0.593 | 0.018 | Carbonic anhydrase XI inhibitor | 0.018 0.005 DBMET00137 | DBMET00137 | |
| 0.002 | 0.595 | 0.026 | Isoleucine-tRNA ligase inhibitor | 0.026 0.01 DBMET00137 | DBMET00137 | |
| 0.005 | 0.6 | 0.038 | 5 Hydroxytryptamine 2B agonist | 0.038 0.028 DBMET00137 | DBMET00137 | |
| 0 | 0.596 | 0.006 | Integrin alpha5beta6 antagonist | 0.006 0.005 DBMET00137 | DBMET00137 | |
| 0.002 | 0.597 | 0.049 | Uridine phosphorylase inhibitor | 0.049 0.008 DBMET00137 | DBMET00137 | |
| 0.068 | 0.664 | 0.294 | Nitric-oxide synthase stimulant | 0.294 0.013 DBMET00137 | DBMET00137 | |
| 0.015 | 0.613 | 0.19 | Glutamate dehydrogenase inhibitor | 0.19 0.011 DBMET00137 | DBMET00137 | |
| 0.013 | 0.614 | 0.076 | Histamine H2 receptor antagonist | 0.076 0.074 DBMET00137 | DBMET00137 | |
| 0.009 | 0.61 | 0.117 | Glucose-6-phosphate isomerase inhibitor | 0.117 0.004 DBMET00137 | DBMET00137 | |
| 0.002 | 0.604 | 0.018 | Complement factor D inhibitor | 0.018 0.012 DBMET00137 | DBMET00137 | |
| 0.031 | 0.635 | 0.137 | Vanilloid 1 agonist | 0.137 0.054 DBMET00137 | DBMET00137 | |
| 0.009 | 0.613 | 0.128 | Glycine receptor antagonist | 0.128 0.014 DBMET00137 | DBMET00137 | |
| 0.029 | 0.634 | 0.219 | 3C-like protease (Human coronavirus) inhibitor | 0.219 0.042 DBMET00137 | DBMET00137 | |
| 0.006 | 0.612 | 0.155 | Aconitate hydratase inhibitor | 0.155 0.004 DBMET00137 | DBMET00137 | |
| 0.035 | 0.642 | 0.275 | Gastrin inhibitor | 0.275 0.053 DBMET00137 | DBMET00137 | |
| 0.006 | 0.613 | 0.156 | Phenylalanine 4-hydroxylase inhibitor | 0.156 0.011 DBMET00137 | DBMET00137 | |
| 0.006 | 0.613 | 0.055 | Membrane dipeptidase inhibitor | 0.055 0.012 DBMET00137 | DBMET00137 | |
| 0.02 | 0.631 | 0.317 | Succinate dehydrogenase inhibitor | 0.317 0.008 DBMET00137 | DBMET00137 | |
| 0.006 | 0.619 | 0.189 | Histidine decarboxylase inhibitor | 0.189 0.014 DBMET00137 | DBMET00137 | |
| 0.012 | 0.625 | 0.166 | MAP kinase kinase 2 inhibitor | 0.166 0.107 DBMET00137 | DBMET00137 | |
| 0.018 | 0.631 | 0.158 | HIV-1 integrase (Overall Integration) inhibitor | 0.158 0.023 DBMET00137 | DBMET00137 | |
| 0.012 | 0.626 | 0.08 | Dihydroorotate oxidase inhibitor | 0.08 0.01 DBMET00137 | DBMET00137 | |
| 0.016 | 0.631 | 0.151 | Protein kinase stimulant | 0.151 0.068 DBMET00137 | DBMET00137 | |
| 0.007 | 0.623 | 0.149 | Psychostimulant | 0.149 0.117 DBMET00137 | DBMET00137 | |
| 0.019 | 0.635 | 0.257 | 5 Hydroxytryptamine 1E antagonist | 0.257 0.067 DBMET00137 | DBMET00137 | |
| 0.005 | 0.621 | 0.167 | Catalase inhibitor | 0.167 0.022 DBMET00137 | DBMET00137 | |
| 0.003 | 0.62 | 0.047 | Thymidylate synthase inhibitor | 0.047 0.031 DBMET00137 | DBMET00137 | |
| 0.004 | 0.621 | 0.03 | Dipeptidyl peptidase II inhibitor | 0.03 0.026 DBMET00137 | DBMET00137 | |
| 0.002 | 0.619 | 0.025 | Sodium/glucose cotransporter 2 inhibitor | 0.025 0.021 DBMET00137 | DBMET00137 | |
| 0.007 | 0.626 | 0.054 | AICAR transformylase inhibitor | 0.054 0.018 DBMET00137 | DBMET00137 | |
| 0.007 | 0.626 | 0.087 | NMDA receptor agonist | 0.087 0.025 DBMET00137 | DBMET00137 | |
| 0.005 | 0.624 | 0.074 | Inducible nitric-oxide synthase inhibitor | 0.074 0.073 DBMET00137 | DBMET00137 | |
| 0.018 | 0.639 | 0.162 | Aldehyde dehydrogenase inhibitor | 0.162 0.041 DBMET00137 | DBMET00137 | |
| 0.002 | 0.624 | 0.036 | Free fatty acid receptor 1 antagonist | 0.036 0.02 DBMET00137 | DBMET00137 | |
| 0.001 | 0.623 | 0.037 | Carbonic anhydrase VIII inhibitor | 0.037 0.004 DBMET00137 | DBMET00137 | |
| 0.001 | 0.623 | 0.037 | Carbonic anhydrase X inhibitor | 0.037 0.004 DBMET00137 | DBMET00137 | |
| 0.008 | 0.632 | 0.073 | Glutamate (mGluR8) agonist | 0.073 0.005 DBMET00137 | DBMET00137 | |
| 0.005 | 0.631 | 0.287 | Porphobilinogen synthase inhibitor | 0.287 0.005 DBMET00137 | DBMET00137 | |
| 0.009 | 0.635 | 0.065 | Histone deacetylase SIRT3 inhibitor | 0.065 0.037 DBMET00137 | DBMET00137 | |
| 0 | 0.636 | 0.023 | Lysophosphatidic acid receptor 3 agonist | 0.023 0.005 DBMET00137 | DBMET00137 | |
| 0.013 | 0.649 | 0.652 | Alpha-N-acetylglucosaminidase inhibitor | 0.652 0.003 DBMET00137 | DBMET00137 | |
| 0.009 | 0.651 | 0.056 | Aldosterone antagonist | 0.056 0.023 DBMET00137 | DBMET00137 | |
| 0.021 | 0.664 | 0.481 | Peroxidase inhibitor | 0.481 0.011 DBMET00137 | DBMET00137 | |
| 0.048 | 0.691 | 0.496 | 5 Hydroxytryptamine release inhibitor | 0.496 0.034 DBMET00137 | DBMET00137 | |
| 0.002 | 0.646 | 0.017 | Estrogen-related receptor gamma agonist | 0.017 0.016 DBMET00137 | DBMET00137 | |
| 0.005 | 0.65 | 0.088 | Sphingosine 1-phosphate receptor 4 agonist | 0.088 0.031 DBMET00137 | DBMET00137 | |
| 0.008 | 0.654 | 0.101 | Calcium antagonist | 0.101 0.047 DBMET00137 | DBMET00137 | |
| 0.002 | 0.649 | 0.04 | Diamine oxidase inhibitor | 0.04 0.023 DBMET00137 | DBMET00137 | |
| 0.006 | 0.653 | 0.094 | Anesthetic local | 0.094 0.088 DBMET00137 | DBMET00137 | |
| 0.009 | 0.658 | 0.138 | Pyruvate kinase inhibitor | 0.138 0.126 DBMET00137 | DBMET00137 | |
| 0.013 | 0.665 | 0.128 | Glycine receptor agonist | 0.128 0.011 DBMET00137 | DBMET00137 | |
| 0.017 | 0.67 | 0.15 | Focal adhesion kinase 2 inhibitor | 0.15 0.131 DBMET00137 | DBMET00137 | |
| 0.014 | 0.668 | 0.127 | Sphingomyelinase inhibitor | 0.127 0.036 DBMET00137 | DBMET00137 | |
| 0.026 | 0.681 | 0.114 | Estrogen-related receptor beta agonist | 0.114 0.013 DBMET00137 | DBMET00137 | |
| 0.03 | 0.685 | 0.378 | Superoxide dismutase inhibitor | 0.378 0.031 DBMET00137 | DBMET00137 | |
| 0.004 | 0.659 | 0.171 | Argininosuccinate synthase inhibitor | 0.171 0.01 DBMET00137 | DBMET00137 | |
| 0.006 | 0.662 | 0.088 | Adenylate cyclase 1 inhibitor | 0.088 0.005 DBMET00137 | DBMET00137 | |
| 0.016 | 0.674 | 0.296 | Triose-phosphate isomerase inhibitor | 0.296 0.005 DBMET00137 | DBMET00137 | |
| 0.001 | 0.661 | 0.025 | Telomerase stimulant | 0.025 0.004 DBMET00137 | DBMET00137 | |
| 0.02 | 0.681 | 0.075 | Transcription factor RelA inhibitor | 0.075 0.022 DBMET00137 | DBMET00137 | |
| 0.015 | 0.679 | 0.177 | DOPA decarboxylase inhibitor | 0.177 0.011 DBMET00137 | DBMET00137 | |
| 0.012 | 0.676 | 0.215 | Mannose-6-phosphate isomerase inhibitor | 0.215 0.023 DBMET00137 | DBMET00137 | |
| 0.004 | 0.67 | 0.07 | Histamine H2 receptor agonist | 0.07 0.01 DBMET00137 | DBMET00137 | |
| 0.002 | 0.669 | 0.037 | Epoxide hydrolase 1 inhibitor | 0.037 0.014 DBMET00137 | DBMET00137 | |
| 0.008 | 0.675 | 0.07 | Macrophage migration inhibitory factor inhibitor | 0.07 0.066 DBMET00137 | DBMET00137 | |
| 0.012 | 0.68 | 0.163 | Prolactin inhibitor | 0.163 0.017 DBMET00137 | DBMET00137 | |
| 0.016 | 0.686 | 0.095 | MAP kinase kinase 7 inhibitor | 0.095 0.017 DBMET00137 | DBMET00137 | |
| 0.005 | 0.675 | 0.089 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.089 0.044 DBMET00137 | DBMET00137 | |
| 0.003 | 0.677 | 0.037 | Vanilloid 2 agonist | 0.037 0.005 DBMET00137 | DBMET00137 | |
| 0.033 | 0.708 | 0.27 | Vasodilator, peripheral | 0.27 0.113 DBMET00137 | DBMET00137 | |
| 0.012 | 0.689 | 0.21 | Calpain 2 inhibitor | 0.21 0.179 DBMET00137 | DBMET00137 | |
| 0.002 | 0.681 | 0.049 | Dihydropteroate synthase inhibitor | 0.049 0.018 DBMET00137 | DBMET00137 | |
| 0.012 | 0.691 | 0.049 | Bombesin 2 receptor antagonist | 0.049 0.034 DBMET00137 | DBMET00137 | |
| 0.001 | 0.68 | 0.021 | Thromboxane A2 agonist | 0.021 0.005 DBMET00137 | DBMET00137 | |
| 0.026 | 0.706 | 0.288 | Interleukin agonist | 0.288 0.054 DBMET00137 | DBMET00137 | |
| 0.001 | 0.685 | 0.051 | Arginase inhibitor | 0.051 0.014 DBMET00137 | DBMET00137 | |
| 0.023 | 0.712 | 0.333 | Cholesterol antagonist | 0.333 0.072 DBMET00137 | DBMET00137 | |
| 0.004 | 0.693 | 0.178 | Glutamate decarboxylase inhibitor | 0.178 0.009 DBMET00137 | DBMET00137 | |
| 0.002 | 0.691 | 0.024 | Sodium/glucose cotransporter inhibitor | 0.024 0.023 DBMET00137 | DBMET00137 | |
| 0.007 | 0.698 | 0.078 | Pregnane X receptor antagonist | 0.078 0.007 DBMET00137 | DBMET00137 | |
| 0.003 | 0.694 | 0.032 | Lysophosphatidic acid 2 receptor antagonist | 0.032 0.019 DBMET00137 | DBMET00137 | |
| 0.003 | 0.694 | 0.04 | Angiotensin AT1 receptor antagonist | 0.04 0.033 DBMET00137 | DBMET00137 | |
| 0.003 | 0.695 | 0.035 | Lysophosphatidic acid receptor 1 agonist | 0.035 0.008 DBMET00137 | DBMET00137 | |
| 0.005 | 0.698 | 0.058 | Potassium channel (ATP-sensitive) activator | 0.058 0.018 DBMET00137 | DBMET00137 | |
| 0.015 | 0.709 | 0.141 | Granulocyte macrophage colony stimulating factor agonist | 0.141 0.007 DBMET00137 | DBMET00137 | |
| 0.007 | 0.701 | 0.067 | Kainate receptor agonist | 0.067 0.005 DBMET00137 | DBMET00137 | |
| 0.009 | 0.704 | 0.161 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.161 0.13 DBMET00137 | DBMET00137 | |
| 0.002 | 0.698 | 0.078 | Dopamine D5 agonist | 0.078 0.006 DBMET00137 | DBMET00137 | |
| 0.005 | 0.702 | 0.061 | Potassium channel (Inward rectifier) activator | 0.061 0.019 DBMET00137 | DBMET00137 | |
| 0.014 | 0.711 | 0.098 | Bile acid receptor antagonist | 0.098 0.053 DBMET00137 | DBMET00137 | |
| 0.012 | 0.711 | 0.114 | Glutamate (mGluR6) antagonist | 0.114 0.007 DBMET00137 | DBMET00137 | |
| 0.021 | 0.721 | 0.131 | Glutamate (mGluR7) agonist | 0.131 0.021 DBMET00137 | DBMET00137 | |
| 0.018 | 0.721 | 0.215 | Antithrombotic | 0.215 0.159 DBMET00137 | DBMET00137 | |
| 0.006 | 0.711 | 0.14 | Aminopeptidase I inhibitor | 0.14 0.014 DBMET00137 | DBMET00137 | |
| 0.014 | 0.72 | 0.269 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.269 0.034 DBMET00137 | DBMET00137 | |
| 0.007 | 0.714 | 0.082 | Protease 3C (Human rhinovirus) inhibitor | 0.082 0.026 DBMET00137 | DBMET00137 | |
| 0.015 | 0.722 | 0.069 | Immunoglobulin Fc receptor antagonist | 0.069 0.012 DBMET00137 | DBMET00137 | |
| 0.002 | 0.711 | 0.057 | GABA uptake inhibitor | 0.057 0.011 DBMET00137 | DBMET00137 | |
| 0.028 | 0.738 | 0.297 | Insulysin inhibitor | 0.297 0.06 DBMET00137 | DBMET00137 | |
| 0.006 | 0.716 | 0.11 | GABA aminotransferase inhibitor | 0.11 0.021 DBMET00137 | DBMET00137 | |
| 0.002 | 0.713 | 0.025 | Protease (Human cytomegalovirus) inhibitor | 0.025 0.011 DBMET00137 | DBMET00137 | |
| 0.008 | 0.721 | 0.101 | GABA B receptor agonist | 0.101 0.016 DBMET00137 | DBMET00137 | |
| 0.014 | 0.728 | 0.138 | Sphingosine 1-phosphate receptor 4 antagonist | 0.138 0.045 DBMET00137 | DBMET00137 | |
| 0.012 | 0.729 | 0.147 | Anabolic | 0.147 0.019 DBMET00137 | DBMET00137 | |
| 0.001 | 0.724 | 0.05 | Glutamate (mGluR1a) agonist | 0.05 0.005 DBMET00137 | DBMET00137 | |
| 0.007 | 0.731 | 0.14 | Cholesterol synthesis inhibitor | 0.14 0.05 DBMET00137 | DBMET00137 | |
| 0.012 | 0.738 | 0.13 | Thiol protease inhibitor | 0.13 0.097 DBMET00137 | DBMET00137 | |
| 0.007 | 0.734 | 0.075 | Ryanodine receptor antagonist | 0.075 0.012 DBMET00137 | DBMET00137 | |
| 0.003 | 0.733 | 0.067 | Androgen agonist | 0.067 0.034 DBMET00137 | DBMET00137 | |
| 0.004 | 0.737 | 0.063 | Squalene epoxidase inhibitor | 0.063 0.018 DBMET00137 | DBMET00137 | |
| 0.002 | 0.736 | 0.037 | Nicotinic acid receptor 2 antagonist | 0.037 0.006 DBMET00137 | DBMET00137 | |
| 0.002 | 0.736 | 0.033 | ATP citrate lysase inhibitor | 0.033 0.021 DBMET00137 | DBMET00137 | |
| 0.006 | 0.744 | 0.102 | Urease inhibitor | 0.102 0.064 DBMET00137 | DBMET00137 | |
| 0.014 | 0.751 | 0.195 | Adenylate cyclase stimulant | 0.195 0.016 DBMET00137 | DBMET00137 | |
| 0.011 | 0.749 | 0.181 | Aminopeptidase B inhibitor | 0.181 0.026 DBMET00137 | DBMET00137 | |
| 0.013 | 0.753 | 0.136 | DNA methylase inhibitor | 0.136 0.131 DBMET00137 | DBMET00137 | |
| 0 | 0.741 | 0.01 | Thromboxane agonist | 0.01 0.008 DBMET00137 | DBMET00137 | |
| 0.007 | 0.749 | 0.075 | Interferon inducer | 0.075 0.029 DBMET00137 | DBMET00137 | |
| 0.002 | 0.746 | 0.023 | Antibiotic Anthracycline-like | 0.023 0.007 DBMET00137 | DBMET00137 | |
| 0.008 | 0.756 | 0.219 | Arachidonic acid antagonist | 0.219 0.018 DBMET00137 | DBMET00137 | |
| 0.006 | 0.756 | 0.036 | Hedgehog signaling activator | 0.036 0.006 DBMET00137 | DBMET00137 | |
| 0.003 | 0.753 | 0.03 | Peptide deformylase inhibitor | 0.03 0.021 DBMET00137 | DBMET00137 | |
| 0.006 | 0.758 | 0.145 | Mucolytic | 0.145 0.036 DBMET00137 | DBMET00137 | |
| 0.027 | 0.779 | 0.102 | CC chemokine 5 receptor agonist | 0.102 0.019 DBMET00137 | DBMET00137 | |
| 0.003 | 0.757 | 0.049 | Dihydroorotase inhibitor | 0.049 0.026 DBMET00137 | DBMET00137 | |
| 0.001 | 0.758 | 0.024 | Retinoid X beta receptor antagonist | 0.024 0.008 DBMET00137 | DBMET00137 | |
| 0.004 | 0.761 | 0.069 | Lysophosphatidic acid 3 receptor antagonist | 0.069 0.015 DBMET00137 | DBMET00137 | |
| 0.013 | 0.771 | 0.15 | Carbonic anhydrase XV inhibitor | 0.15 0.031 DBMET00137 | DBMET00137 | |
| 0.01 | 0.771 | 0.139 | DNA methyltransferase I inhibitor | 0.139 0.117 DBMET00137 | DBMET00137 | |
| 0.002 | 0.765 | 0.073 | Carbonic anhydrase VB inhibitor | 0.073 0.026 DBMET00137 | DBMET00137 | |
| 0.004 | 0.767 | 0.037 | Melatonin receptor 1A agonist | 0.037 0.018 DBMET00137 | DBMET00137 | |
| 0.002 | 0.765 | 0.027 | Prostaglandin F2 alpha agonist | 0.027 0.011 DBMET00137 | DBMET00137 | |
| 0.005 | 0.769 | 0.188 | Calpain inhibitor | 0.188 0.125 DBMET00137 | DBMET00137 | |
| 0.013 | 0.78 | 0.129 | Carbonic anhydrase III inhibitor | 0.129 0.039 DBMET00137 | DBMET00137 | |
| 0.01 | 0.778 | 0.055 | Topoisomerase II beta inhibitor | 0.055 0.027 DBMET00137 | DBMET00137 | |
| 0.001 | 0.77 | 0.046 | Fructose-1,6-bisphosphatase inhibitor | 0.046 0.029 DBMET00137 | DBMET00137 | |
| 0.004 | 0.774 | 0.108 | Alcohol dehydrogenase inhibitor | 0.108 0.044 DBMET00137 | DBMET00137 | |
| 0.01 | 0.78 | 0.184 | Transcription factor STAT3 inhibitor | 0.184 0.158 DBMET00137 | DBMET00137 | |
| 0 | 0.771 | 0.019 | Glutamate (mGluR6) agonist | 0.019 0.004 DBMET00137 | DBMET00137 | |
| 0.005 | 0.779 | 0.056 | Glucosylceramidase inhibitor | 0.056 0.036 DBMET00137 | DBMET00137 | |
| 0.005 | 0.781 | 0.09 | Interferon agonist | 0.09 0.038 DBMET00137 | DBMET00137 | |
| 0.019 | 0.796 | 0.278 | Vasodilator, coronary | 0.278 0.107 DBMET00137 | DBMET00137 | |
| 0.004 | 0.783 | 0.116 | Expectorant | 0.116 0.054 DBMET00137 | DBMET00137 | |
| 0.003 | 0.784 | 0.07 | Carbonic anhydrase V inhibitor | 0.07 0.042 DBMET00137 | DBMET00137 | |
| 0.016 | 0.797 | 0.188 | Amylase inhibitor | 0.188 0.048 DBMET00137 | DBMET00137 | |
| 0.001 | 0.783 | 0.023 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.023 0.017 DBMET00137 | DBMET00137 | |
| 0.013 | 0.797 | 0.157 | Cyclooxygenase 3 inhibitor | 0.157 0.042 DBMET00137 | DBMET00137 | |
| 0.018 | 0.802 | 0.162 | Hexokinase inhibitor | 0.162 0.066 DBMET00137 | DBMET00137 | |
| 0.003 | 0.788 | 0.03 | Glutamate (mGluR1) agonist | 0.03 0.01 DBMET00137 | DBMET00137 | |
| 0.003 | 0.787 | 0.105 | Na+ K+ transporting ATPase inhibitor | 0.105 0.027 DBMET00137 | DBMET00137 | |
| 0.003 | 0.788 | 0.033 | Calcitonin receptor agonist | 0.033 0.024 DBMET00137 | DBMET00137 | |
| 0.019 | 0.807 | 0.188 | CF transmembrane conductance regulator agonist | 0.188 0.029 DBMET00137 | DBMET00137 | |
| 0.009 | 0.798 | 0.168 | Cathepsin H inhibitor | 0.168 0.035 DBMET00137 | DBMET00137 | |
| 0.006 | 0.796 | 0.054 | Botulinum neurotoxin type A inhibitor | 0.054 0.048 DBMET00137 | DBMET00137 | |
| 0.004 | 0.794 | 0.076 | Carbonic anhydrase VA inhibitor | 0.076 0.04 DBMET00137 | DBMET00137 | |
| 0.004 | 0.795 | 0.055 | Heparanase inhibitor | 0.055 0.033 DBMET00137 | DBMET00137 | |
| 0.015 | 0.809 | 0.155 | Photosensitizer | 0.155 0.028 DBMET00137 | DBMET00137 | |
| 0.007 | 0.802 | 0.126 | Neuropeptide Y1 antagonist | 0.126 0.108 DBMET00137 | DBMET00137 | |
| 0.009 | 0.805 | 0.122 | Adenylate cyclase inhibitor | 0.122 0.066 DBMET00137 | DBMET00137 | |
| 0.001 | 0.798 | 0.04 | Retinoid X alpha receptor agonist | 0.04 0.019 DBMET00137 | DBMET00137 | |
| 0.001 | 0.798 | 0.038 | Retinoid X receptor agonist | 0.038 0.024 DBMET00137 | DBMET00137 | |
| 0.004 | 0.801 | 0.067 | Sphingosine kinase 2 inhibitor | 0.067 0.024 DBMET00137 | DBMET00137 | |
| 0.006 | 0.804 | 0.085 | Myeloperoxidase inhibitor | 0.085 0.057 DBMET00137 | DBMET00137 | |
| 0.005 | 0.804 | 0.056 | Cytokine production stimulant | 0.056 0.018 DBMET00137 | DBMET00137 | |
| 0.016 | 0.818 | 0.161 | Histone acetyltransferase inhibitor | 0.161 0.125 DBMET00137 | DBMET00137 | |
| 0.008 | 0.812 | 0.088 | Glutathione S-transferase inhibitor | 0.088 0.05 DBMET00137 | DBMET00137 | |
| 0.005 | 0.813 | 0.039 | Retinoid X alpha receptor antagonist | 0.039 0.017 DBMET00137 | DBMET00137 | |
| 0.016 | 0.825 | 0.186 | Interferon gamma antagonist | 0.186 0.047 DBMET00137 | DBMET00137 | |
| 0.005 | 0.814 | 0.173 | Insulin sensitizer | 0.173 0.104 DBMET00137 | DBMET00137 | |
| 0.005 | 0.818 | 0.043 | Retinoid X receptor antagonist | 0.043 0.019 DBMET00137 | DBMET00137 | |
| 0.012 | 0.832 | 0.18 | ATPase inhibitor | 0.18 0.058 DBMET00137 | DBMET00137 | |
| 0.003 | 0.825 | 0.058 | Leukotriene C antagonist | 0.058 0.035 DBMET00137 | DBMET00137 | |
| 0.007 | 0.83 | 0.158 | Toll-Like receptor 2 antagonist | 0.158 0.047 DBMET00137 | DBMET00137 | |
| 0.004 | 0.829 | 0.155 | Sphingosine 1-phosphate receptor 2 antagonist | 0.155 0.034 DBMET00137 | DBMET00137 | |
| 0.002 | 0.832 | 0.054 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.054 0.047 DBMET00137 | DBMET00137 | |
| 0.01 | 0.842 | 0.164 | Melanin inhibitor | 0.164 0.065 DBMET00137 | DBMET00137 | |
| 0.007 | 0.841 | 0.084 | Xanthine oxidase inhibitor | 0.084 0.083 DBMET00137 | DBMET00137 | |
| 0.001 | 0.837 | 0.025 | Neuraminidase (Influenza B) inhibitor | 0.025 0.008 DBMET00137 | DBMET00137 | |
| 0.004 | 0.841 | 0.077 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.077 0.018 DBMET00137 | DBMET00137 | |
| 0.004 | 0.841 | 0.075 | Carbonic anhydrase stimulant | 0.075 0.029 DBMET00137 | DBMET00137 | |
| 0.006 | 0.845 | 0.084 | Carbonic anhydrase XIII inhibitor | 0.084 0.047 DBMET00137 | DBMET00137 | |
| 0.006 | 0.846 | 0.1 | Proteasome inhibitor | 0.1 0.088 DBMET00137 | DBMET00137 | |
| 0.007 | 0.848 | 0.169 | Sphingosine 1-phosphate receptor 5 antagonist | 0.169 0.034 DBMET00137 | DBMET00137 | |
| 0.004 | 0.848 | 0.06 | Beta 3 adrenoreceptor antagonist | 0.06 0.056 DBMET00137 | DBMET00137 | |
| 0.012 | 0.857 | 0.193 | Phospholipase C inhibitor | 0.193 0.049 DBMET00137 | DBMET00137 | |
| 0.002 | 0.849 | 0.037 | Leukotriene C4 antagonist | 0.037 0.032 DBMET00137 | DBMET00137 | |
| 0.007 | 0.856 | 0.047 | CD45 antagonist | 0.047 0.042 DBMET00137 | DBMET00137 | |
| 0.005 | 0.857 | 0.104 | Ornithine decarboxylase inhibitor | 0.104 0.04 DBMET00137 | DBMET00137 | |
| 0.002 | 0.859 | 0.039 | Sphingosine kinase 1 inhibitor | 0.039 0.032 DBMET00137 | DBMET00137 | |
| 0.002 | 0.86 | 0.042 | Glutamate (mGluR3) agonist | 0.042 0.008 DBMET00137 | DBMET00137 | |
| 0.001 | 0.864 | 0.041 | Potassium channel Kv1.3 blocker | 0.041 0.04 DBMET00137 | DBMET00137 | |
| 0.008 | 0.876 | 0.095 | Carbonic anhydrase VI inhibitor | 0.095 0.042 DBMET00137 | DBMET00137 | |
| 0.002 | 0.876 | 0.06 | Sphingosine kinase inhibitor | 0.06 0.038 DBMET00137 | DBMET00137 | |
| 0.002 | 0.877 | 0.058 | Sphingosine 1-phosphate receptor 3 antagonist | 0.058 0.042 DBMET00137 | DBMET00137 | |
| 0.005 | 0.881 | 0.188 | Transcription factor NF kappa B inhibitor | 0.188 0.181 DBMET00137 | DBMET00137 | |
| 0.005 | 0.883 | 0.108 | Keratolytic | 0.108 0.026 DBMET00137 | DBMET00137 | |
| 0.006 | 0.886 | 0.179 | Neurotensin receptor agonist | 0.179 0.05 DBMET00137 | DBMET00137 | |
| 0.002 | 0.884 | 0.059 | Beta 2 adrenoreceptor agonist | 0.059 0.054 DBMET00137 | DBMET00137 | |
| 0.004 | 0.895 | 0.173 | Immunostimulant | 0.173 0.137 DBMET00137 | DBMET00137 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |